The role and therapeutic potential of ser/thr phosphatase PP2A in apoptotic signalling networks in human cancer cells

Current Molecular Medicine

Volumn 12, Issue 3, 2012, Pages 268-287

  Janssens, V ^a   Rebollo, A ^b  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^b INSERM   (France)

Author keywords

Akt; Apoptosis; Bad; Bcl 2; Cancer; Ceramide; CIP2A; Dependence receptor; FoxO; NFkB; P53; PP1; PP2A; SET; TNF ; TRAIL

Indexed keywords

BORTEZOMIB; CALYCULIN A; CERAMIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DASATINIB; DOXORUBICIN; FAS ANTIGEN; FINGOLIMOD; FORSKOLIN; FOSTRIECIN; HYDROXYTYROSOL; IMATINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NORCANTHARIDIN; P21 ACTIVATED KINASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE C IOTA; PROTEIN MDM2; ROLIPRAM; SORAFENIB; TEMOZOLOMIDE; TIGATUZUMAB; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CAENORHABDITIS ELEGANS; CANCER INHIBITION; CANCER SURVIVAL; CATALYSIS; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DNA BINDING MOTIF; DNA DAMAGE; DOWN REGULATION; DROSOPHILA; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; HEAD AND NECK CANCER; HUMAN; IN VIVO STUDY; LUNG CANCER; MITOCHONDRIAL MEMBRANE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OXIDATIVE STRESS; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION;

APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; HUMANS; NEOPLASMS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 84857133852     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412799218930     Document Type: Article

References (221)

1. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8: 121-132.
2. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010; 16: 4325-4330.
3. Julien SG, Dubé N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 2011; 11: 35-49.
4. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005; 15: 34-41.
5. Virshup DM, Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 2009; 33: 537-545.
6. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001; 353: 417-439.
7. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory supunits and cancer. Biochim Biophys Acta 2009; 1795: 1-15.
8. Götz J, Probst A, Ehler E, Hemmings B, Kues W. Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic supunit Calpha. Proc Natl Acad Sci USA 1998; 95: 12370-12375.
9. Louis JV, Martens E, Borghgraef P, et al. Mice lacking phosphatase PP2A supunit PR61/B'δ(Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3β. Proc Natl Acad Sci USA 2011; 108: 6957-6962.
10. Strack S, Cribbs JT, Gomez L. Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival. J Biol Chem 2004; 279: 47732-47739.
11. Chen W, Arroyo JD, Timmons JC, Possemato R, Hahn WC. Cancer-associated PP2A Aalpha supunits induce functional haploinsufficiency and tumorigenicity. Cancer Res 2005; 65: 8183-8192.
12. Sablina AA, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 2010; 70: 10474-10484.
13. Li X, Scuderi A, Letsou A, Virshup DM. B56-associated protein phosphatase 2A is required for survival and protects from apoptosis in Drosophila melanogaster. Mol Cell Biol 2002; 22: 3674-3684.
14. Silverstein AM, Barrow CA, Davis AJ, Mumby MC. Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory supunits. Proc Natl Acad Sci USA 2002; 99: 4221-4226.
15. Kong M, Fox CJ, Mu J, et al. The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis. Science 2004; 306: 695-698.
16. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005; 7: 591-600.
17. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene 2005; 24: 7746-7755.
18. Arnold HK, Sears RC. A tumor suppressor role for PP2AB56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev 2008; 27: 147-158.
19. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14: 152-160.
20. Janssens V, Longin S, Goris J. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci 2008; 33: 113-121.
21. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008; 27: 6398-6406.
22. Garcia A, Cayla X, Guergnon J, et al. Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie 2003; 85: 721-726.
23. Danial NN. BAD: undertaker by night, candyman by day. Oncogene 2008; 27: S53-S70.
24. Desai S, Pillai P, Win-Piazza H, Acevedo-Duncan M. PKC-1 promotes glioblastoma cell survival by phosphorylating and inhibiting BAD through a phosphatidylinositol 3-kinase pathway. Biochim Biophys Acta 2011; 1813: 1190-1197.
25. Datta SR, Katsov A, Hu L, et al. 14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 2000; 6: 41-51.
26. Chiang CW, Harris G, Ellig C, et al. Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin- 3-dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation. Blood 2001; 97: 1289-1297.
27. Chiang CW, Kanies C, Kim KW, et al. Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol Cell Biol 2003; 23: 6350-6362.
28. Wang HG, Pathan N, Ethell IM, et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999; 284: 339-343.
29. Klumpp S, Selke D, Krieglstein J. Protein phosphatase type 2C dephosphorylates BAD. Neurochem Int 2003; 42: 555-560.
30. Ayllón V, Martínez AC, García A, Cayla X, Rebollo A. Protein phosphatase 1alpha is a Ras-activated Bad phosphatase that regulates interleukin-2 deprivation-induced apoptosis. EMBO J 2000; 19: 2237-2246.
31. Ayllón V, Cayla X, García A, et al. Bcl-2 targets protein phosphatase 1 alpha to Bad. J Immunol 2001; 166: 7345-7352.
32. Ayllón V, Cayla X, García A, Fleischer A, Rebollo A. The anti-apoptotic molecules Bcl-xL and Bcl-w target protein phosphatase 1alpha to Bad. Eur J Immunol 2002; 32: 1847-1855.
33. Egloff MP, Johnson DF, Moorhead G, Cohen PT, Cohen P, Barford D. Structural basis for the recognition of regulatory supunits by the catalytic supunit of protein phosphatase 1. EMBO J 1997; 16: 1876-1887.
34. Ruvolo PP, Deng X, Carr BK, May WS. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 1998; 273: 25436-25442.
35. Deng X, Ruvolo P, Carr B, May WS Jr. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA 2000; 97: 1578-1583.
36. Tamura Y, Simizu S, Osada H. The phosphorylation status and anti-apoptotic activity of Bcl-2 are regulated by ERK and protein phosphatase 2A on the mitochondria. FEBS Lett 2004; 569: 249-255.
37. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May WS Jr. Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 2001; 276: 23681-32368.
38. Ruvolo PP, Deng X, Ito T, Carr BK, May WS. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J Biol Chem 1999; 274: 20296-20300.
39. Ruvolo PP, Clark W, Mumby M, Gao F, May WS. A functional role for the B56 alpha-supunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. J Biol Chem 2002; 277: 22847-22852.
40. Jiffar T, Kurinna S, Suck G, et al. PKC alpha mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation. Leukemia 2004; 18: 505-512.
41. Ruvolo VR, Kurinna SM, Karanjeet KB, et al. PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. J Biol Chem 2008; 283: 35474-35485.
42. Deng X, Gao F, May WS. Protein phosphatase 2A inactivates Bcl2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-P53 binding. Blood 2009; 113: 422-428.
43. Lin SS, Bassik MC, Suh H, et al. PP2A regulates BCL-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. J Biol Chem 2006; 281: 23003-23012.
44. Simizu S, Tamura Y, Osada H. Dephosphorylation of Bcl-2 by protein phosphatase 2A results in apoptosis resistance. Cancer Sci 2004; 95: 266-270.
45. Xin M, Deng X. Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation. J Biol Chem 2006; 281: 18859-18867.
46. Antony R, Lukiw WJ, Bazan NG. Neuroprotectin D1 induces dephosphorylation of Bcl-xL in a PP2A-dependent manner during oxidative stress and promotes retinal pigment epithelial cell survival. J Biol Chem 2010; 285: 18301-18308.
47. Dagda RK, Zaucha JA, Wadzinski BE, Strack S. A developmentally regulated, neuron-specific splice variant of the variable supunit Btargets protein phosphatase 2A to mitochondria and modulates apoptosis. J Biol Chem 2003; 278: 24976-24985.
48. Dagda RK, Merrill RA, Cribbs JT, et al. The spinocerebellar ataxia 12 gene product and protein phosphatase 2A regulatory supunit Bbeta2 antagonizes neuronal survival by promoting mitochondrial fission. J Biol Chem 2008; 283: 36241-36248.
49. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.
50. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011; 1813: 1978-1986.
51. Dai C, Gu W. P53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 2010; 16: 528-536.
52. Maclaine NJ, Hupp TR. The regulation of P53 by phosphorylation: a model for how distinct signals integrate into the P53 pathway. Aging 2009; 1: 490-502.
53. Maclaine NJ, Hupp TR. How phosphorylation controls p53. Cell Cycle 2011; 10: 916-921.
54. Li HH, Cai X, Shouse GP, Piluso LG, Liu X. A specific PP2A regulatory supunit, B56gamma, mediates DNA damageinduced dephosphorylation of P53 at Thr55. EMBO J 2007; 26: 402-411.
55. Shouse GP, Cai X, Liu X. Serine 15 phosphorylation of P53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol 2008; 28: 448-456.
56. Shouse GP, Nobumori Y, Panowicz MJ, Liu X. ATMmediated phosphorylation activates the tumor-suppressive function of B56-PP2A. Oncogene 2011; 30: 3755-3765
57. Shouse GP, Nobumori Y, Liu X. A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A. Oncogene 2010; 29: 3933-3941.
58. Haneda M, Kojima E, Nishikimi A, Hasegawa T, Nakashima I, Isobe K. Protein phosphatase 1, but not protein phosphatase 2A, dephosphorylates DNA-damaging stressinduced phospho-serine 15 of p53. FEBS Lett 2004; 567: 171-174.
59. Li DW, Liu JP, Schmid PC, et al. Protein serine/threonine phosphatase-1 dephosphorylates P53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities. Oncogene 2006; 25: 3006-3022.
60. Qin J, Chen HG, Yan Q, et al. Protein phosphatase-2A is a target of epigallocatechin-3-gallate and modulates p53-Bak apoptotic pathway. Cancer Res 2008; 68: 4150-4162. Erratum in: Cancer Res 2008; 68: 6859.
61. Dohoney KM, Guillerm C, Whiteford C, et al. Phosphorylation of P53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage. Oncogene 2004; 23: 49-57.
62. Mi J, Bolesta E, Brautigan DL, Larner JM. PP2A regulates ionizing radiation-induced apoptosis through Ser46 phosphorylation of p53. Mol Cancer Ther 2009; 8: 135-140.
63. Long X, Wu G, Gaa ST, Rogers TB. Inhibition of protein phosphatase-1 is linked to phosphorylation of P53 and apoptosis. Apoptosis 2002; 7: 31-39.
64. Meek DW, Hupp TR. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours? Semin Cancer Biol 2010; 20: 19-28.
65. Okamoto K, Kamibayashi C, Serrano M, Prives C, Mumby MC, Beach D. p53-dependent association between cyclin G and the B' supunit of protein phosphatase 2A. Mol Cell Biol 1996; 16: 6593-6602.
66. Okamoto K, Li H, Jensen MR, et al. Cyclin G recruits PP2A to dephosphorylate Mdm2. Mol Cell 2002; 9: 761-771.
67. Kimura SH, Nojima H. Cyclin G1 associates with MDM2 and regulates accumulation and degradation of P53 protein. Genes Cells 2002; 7: 869-880.
68. Ito A, Kataoka TR, Watanabe M, et al. A truncated isoform of the PP2A B56 supunit promotes cell motility through paxillin phosphorylation. EMBO J 2000; 19: 562-571.
69. Koma YI, Ito A, Watabe K, Kimura SH, Kitamura Y. A truncated isoform of the PP2A B56gamma regulatory supunit reduces irradiation-induced Mdm2 phosphorylation and could contribute to metastatic melanoma cell radioresistance. Histol Histopathol 2004; 19: 391-400.
70. Nho RS, Kahm J. Beta1-Integrin-collagen interaction suppresses FoxO3a by the coordination of Akt and PP2A. J Biol Chem 2010; 285: 14195-141209.
71. Yang JY, Zong CS, Xia W, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008; 10: 138-148.
72. Hu MC, Lee DF, Xia W, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117: 225-237. Erratum in: Cell 2007; 129: 1427-1428.
73. Yan L, Lavin VA, Moser LR, Cui Q, Kanies C, Yang E. PP2A regulates the pro-apoptotic activity of FOXO1. J Biol Chem 2008; 283: 7411-7420.
74. Barreyro FJ, Kobayashi S, Bronk SF, Werneburg NW, Malhi H, Gores GJ. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem 2007; 282: 27141-27154.
75. Bertoli C, Copetti T, Lam EW, Demarchi F, Schneider C. Calpain small-1 modulates Akt/FoxO3A signaling and apoptosis through PP2A. Oncogene 2009; 28: 721-733.
76. Singh A, Ye M, Bucur O, et al. Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 2010; 21: 1140-1152.
77. Yin KJ, Hsu CY, Hu XY, et al. Protein phosphatase 2A regulates bim expression via the Akt/FKHRL1 signaling pathway in amyloid-beta peptide-induced cerebrovascular endothelial cell death. J Neurosci 2006; 26: 2290-2299.
78. Parcellier A, Tintignac LA, Zhuravleva E, Hemmings BA. PKB and the mitochondria: AKTing on apoptosis. Cell Signal 2008; 20: 21-30.
79. Bozulic L, Hemmings BA. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 2009; 21: 256-261.
80. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261-273.
81. Ni YG, Wang N, Cao DJ, et al. FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci USA 2007; 104: 20517-20522.
82. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006; 441: 523-527.
83. Rocher G, Letourneux C, Lenormand P, Porteu F. Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. J Biol Chem 2007; 282: 5468-5477.
84. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005; 18: 13-24.
85. Rodgers JT, Vogel RO, Puigserver P. Clk2 and B56β mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt. Mol Cell 2011; 41: 471-479.
86. Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 2007; 25: 917-931.
87. Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory supunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem 2008; 283: 1882-1892.
88. Padmanabhan S, Mukhopadhyay A, Narasimhan SD, Tesz G, Czech MP, Tissenbaum HA. A PP2A regulatory supunit regulates C. elegans insulin/IGF-1 signaling by modulating AKT-1 phosphorylation. Cell 2009; 136: 939-951.
89. Van Kanegan MJ, Adams DG, Wadzinski BE, Strack S. Distinct protein phosphatase 2A heterotrimers modulate growth factor signaling to extracellular signal-regulated kinases and Akt. J Biol Chem 2005; 280: 36029-36036.
90. Vereshchagina N, Ramel MC, Bitoun E, Wilson C. The protein phosphatase PP2A-B' supunit Widerborst is a negative regulator of cytoplasmic activated Akt and lipid metabolism in Drosophila. J Cell Sci 2008; 121: 3383-3392.
91. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004; 5: 127-136.
92. Ruvolo PP, Qui YH, Coombes KR, et al. Low expression of PP2A regulatory supunit B55 is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia 2011; 25: 1711-1717.
93. Swingle M, Ni L, Honkanen RE. Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol 2007; 365: 23-38.
94. Ray RM, Bhattacharya S, Johnson LR. Protein phosphatase 2A regulates apoptosis in intestinal epithelial cells. J Biol Chem 2005; 280: 31091-310100.
95. Li M, Makkinje A, Damuni Z. The myeloid leukemiaassociated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996; 271: 11059-11062.
96. Härmälä-Braskén AS, Mikhailov A, Söderström TS, et al. Type-2A protein phosphatase activity is required to maintain death receptor responsiveness. Oncogene 2003; 22: 7677-7686.
97. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-371.
98. Li H, Lin X. Positive and negative signaling components involved in TNFalpha-induced NF-kappaB activation. Cytokine 2008; 41: 1-8.
99. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 1995; 14: 2876-2883.
100. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997; 388: 548-554.
101. Sontag E, Sontag JM, Garcia A. Protein phosphatase 2A is a critical regulator of protein kinase C zeta signaling targeted by SV40 small t to promote cell growth and NF-kappaB activation. EMBO J 1997; 16: 5662-5671.
102. Moreno CS, Ramachandran S, Ashby DG, et al. Signaling and transcriptional changes critical for transformation of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A B56gamma knockdown. Cancer Res 2004; 64: 6978-6988.
103. Fu DX, Kuo YL, Liu BY, Jeang KT, Giam CZ. Human Tlymphotropic virus type I tax activates I-kappa B kinase by inhibiting I-kappa B kinase-associated serine/threonine protein phosphatase 2A. J Biol Chem 2003; 278: 1487-1493.
104. Hong S, Wang LC, Gao X, et al. Heptad repeats regulate protein phosphatase 2a recruitment to I-kappaB kinase gamma/NF-kappaB essential modulator and are targeted by human T-lymphotropic virus type 1 tax. J Biol Chem 2007; 282: 12119-12126.
105. Li S, Wang L, Berman MA, Zhang Y, Dorf ME. RNAi screen in mouse astrocytes identifies phosphatases that regulate NF-kappaB signaling. Mol Cell 2006; 24: 497-509.
106. Barisic S, Strozyk E, Peters N, Walczak H, Kulms D. Identification of PP2A as a crucial regulator of the NFkappaB feedback loop: its inhibition by UVB turns NFkappaB into a pro-apoptotic factor. Cell Death Differ 2008; 15: 1681-1690.
107. Zheng L, Liu J, Batalov S, et al. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci USA 2004; 101: 135-140.
108. Yang J, Fan GH, Wadzinski BE, Sakurai H, Richmond A. Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem 2001; 276: 47828-47833.
109. Kray AE, Carter RS, Pennington KN, et al. Positive regulation of IkappaB kinase signaling by protein serine/threonine phosphatase 2A. J Biol Chem 2005; 280: 35974-35982.
110. Witt J, Barisic S, Schumann E, et al. Mechanism of PP2Amediated IKK beta dephosphorylation: a systems biological approach. BMC Syst Biol 2009; 3: 71.
111. Palkowitsch L, Leidner J, Ghosh S, Marienfeld RB. Phosphorylation of serine 68 in the IkappaB kinase (IKK)-binding domain of NEMO interferes with the structure of the IKK complex and tumor necrosis factor-alpha-induced NFkappaB activity. J Biol Chem 2008; 283: 76-86.
112. Yang J, Lin Y, Guo Z, et al. The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat Immunol 2001; 2: 620-624.
113. Fritz A, Brayer KJ, McCormick N, Adams DG, Wadzinski BE, Vaillancourt RR. Phosphorylation of serine 526 is required for MEKK3 activity, and association with 14-3-3 blocks dephosphorylation. J Biol Chem 2006; 281: 6236-6245.
114. Sun W, Wang H, Zhao X, et al. Protein phosphatase 2A acts as a mitogen-activated protein kinase kinase kinase 3 (MEKK3) phosphatase to inhibit lysophosphatidic acidinduced IkappaB kinase beta/nuclear factor-kappaB activation. J Biol Chem 2010; 285: 21341-21348.
115. Liu J, Lin A. Wiring the cell signaling circuitry by the NFkappa B and JNK1 crosstalk and its applications in human diseases. Oncogene 2007; 26: 3267-3278.
116. Zhao B, Sun L, Haas M, Denenberg AG, Wong HR, Shanley TP. PP2A regulates upstream members of the c-jun Nterminal kinase mitogen-activated protein kinase signaling pathway. Shock 2008; 29: 181-188.
117. Min W, Lin Y, Tang S, et al. AIP1 recruits phosphatase PP2A to ASK1 in tumor necrosis factor-induced ASK1-JNK activation. Circ Res 2008; 102: 840-848.
118. Zhang H, Zhang H, Lin Y, Li J, Pober JS, Min W. RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is critical for tumor necrosis factor-induced ASK1-JNK/P38 activation. J Biol Chem 2007; 282: 14788-14796.
119. Zhang R, He X, Liu W, Lu M, Hsieh JT, Min W. AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. J Clin Invest 2003; 111: 1933-1943.
120. De Chiara G, Marcocci ME, Torcia M, et al. Bcl-2 Phosphorylation by P38 MAPK: identification of target sites and biologic consequences. J Biol Chem 2006; 281: 21353-21361.
121. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-2849.
122. Alvarado-Kristensson M, Melander F, Leandersson K, Ronnstrand L, Wernstedt C, Andersson T. P38 -MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J Exp Med 2004; 199: 449-458.
123. Alvarado-Kristensson M, Andersson T. Protein phosphatase 2A regulates apoptosis in neutrophils by dephosphorylating both P38 MAPK and its supstrate caspase 3. J Biol Chem 2005; 280: 6238-6244.
124. Avdi NJ, Malcolm KC, Nick JA, Worthen GS. A role for protein phosphatase-2A in P38 mitogen-activated protein kinase-mediated regulation of the c-Jun NH(2)-terminal kinase pathway in human neutrophils. J Biol Chem 2002; 277: 40687-40696.
125. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008; 22: 954-965.
126. Van Kanegan MJ, Strack S. The protein phosphatase 2A regulatory supunits B'beta and B'delta mediate sustained TrkA neurotrophin receptor autophosphorylation and neuronal differentiation. Mol Cell Biol 2009; 29: 662-674.
127. Zwaenepoel K, Goris J, Erneux C, Parker PJ, Janssens V. Protein phosphatase 2A PR130/B"alpha1 supunit binds to the SH2 domain-containing inositol polyphosphate 5-phosphatase 2 and prevents epidermal growth factor (EGF)-induced EGF receptor degradation sustaining EGF-mediated signaling. FASEB J 2010; 24: 538-547.
128. Li SP, Junttila MR, Han J, Kähäri VM, Westermarck J. P38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2. Cancer Res 2003; 63: 3473-3477.
129. Liu Q, Hofmann PA. Protein phosphatase 2A-mediated cross-talk between P38 MAPK and ERK in apoptosis of cardiac myocytes. Am J Physiol Heart Circ Physiol 2004; 286: H2204-H2212.
130. Grethe S, Pörn-Ares MI. P38 MAPK regulates phosphorylation of Bad via PP2A-dependent suppression of the MEK1/2-ERK1/2 survival pathway in TNF-alpha induced endothelial apoptosis. Cell Signal 2006; 18: 531-540.
131. Prickett TD, Brautigan DL. Cytokine activation of P38 mitogen-activated protein kinase and apoptosis is opposed by alpha-4 targeting of protein phosphatase 2A for sitespecific dephosphorylation of MEK3. Mol Cell Biol 2007; 27: 4217-4227.
132. Santoro MF, Annand RR, Robertson MM, et al. Regulation of protein phosphatase 2A activity by caspase-3 during apoptosis. J Biol Chem 1998; 273: 13119-13128.
133. Jin Z, Wallace L, Harper SQ, Yang J. PP2A:B56{epsilon}, a supstrate of caspase-3, regulates p53-dependent and p53-independent apoptosis during development. J Biol Chem 2010; 285: 34493-34502.
134. Goldschneider D, Mehlen P. Dependence receptors: a new paradigm in cell signaling and cancer therapy. Oncogene 2010; 29: 1865-1882.
135. Mazelin L, Bernet A, Bonod-Bidaud C, et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature 2004; 431: 80-84.
136. Paradisi A, Maisse C, Bernet A, et al. NF-kappaB regulates netrin-1 expression and affects the conditional tumor suppressive activity of the netrin-1 receptors. Gastroenterology 2008; 135: 1248-1257.
137. Llambi F, Lourenço FC, Gozuacik D, et al. The dependence receptor UNC5H2 mediates apoptosis through DAP-kinase. EMBO J 2005; 24: 1192-1201.
138. Guenebeaud C, Goldschneider D, Castets M, et al. The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase. Mol Cell 2010; 40: 863-876.
139. Wang SS, Esplin ED, Li JL, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998; 282: 284-287.
140. Sablina AA, Chen W, Arroyo JD, et al. The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell 2007; 129: 969-982.
141. Junttila MR, Puustinen P, Niemelä M, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130: 51-62.
142. Khanna A, Böckelman C, Hemmes A, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009; 101: 793-805.
143. Widau RC, Jin Y, Dixon SA, Wadzinski BE, Gallagher PJ. Protein phosphatase 2A (PP2A) holoenzymes regulate death-associated protein kinase (DAPK) in ceramide-induced anoikis. J Biol Chem 2010; 285: 13827-13838.
144. Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol 1998; 9: 1873-1880.
145. Fukukawa C, Shima H, Tanuma N, Ogawa K, Kikuchi K. Upregulation of I-2(PP2A)/SET gene expression in rat primary hepatomas and regenerating livers. Cancer Lett 2000; 161: 89-95.
146. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355-368.
147. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408-2421.
148. Cristóbal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011; 25: 606-614.
149. Chao A, Tsai CL, Wei PC, et al. Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett 2010; 291: 99-107.
150. Böckelman C, Hagström J, Mäkinen LK, et al. High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer 2011; 104: 1890-1895.
151. Li W, Ge Z, Liu C, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 2008; 14: 3722-3728.
152. Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 2002; 21: 5006-5015.
153. Vaarala MH, Väisänen MR, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010; 29: 136
154. Côme C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15: 5092-5100.
155. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is overexpressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011; 33: 290-298.
156. Qu W, Li W, Wei L, Xing L, Wang X, Xy J. CIP2A is overexpressed in esophagal squamous cell carcinoma. Med Oncol 2011; (Epub ahead of print) PMID: 21140243.
157. Kappos L, Radue EW, O'Connor P, et al. A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
158. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
159. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 2003; 138: 1303-1312.
160. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer 2006; 95: 775-781.
161. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008; 27: 159-168.
162. Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008; 111: 275-284.
163. Roberts KG, Smith AM, McDougall F, et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 2010; 70: 5438-5447.
164. Lee TK, Man K, Ho JW, et al. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 2004; 25: 2397-2405.
165. Sonoda Y, Yamamoto D, Sakurai S, et al. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem Biophys Res Commun 2001; 281: 282-288.
166. Permpongkosol S, Wang JD, Takahara S, et al. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer 2002; 98: 167-172.
167. Liu Q, Alinari L, Chen CS, et al. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 2010; 16: 3182-3192.
168. Feschenko MS, Stevenson E, Nairn AC, Sweadner KJ. A novel cAMP-stimulated pathway in protein phosphatase 2A activation. J Pharmacol Exp Ther 2002; 302: 111-118.
169. Moon EY, Lerner A. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 2003; 101: 4122-4130.
170. Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res 2003; 47: 383-392.
171. Lin CF, Chen CL, Lin YS. Ceramide in apoptotic signaling and anticancer therapy. Curr Med Chem 2006; 13: 1609-1616.
172. Dobrowsky RT, Kamibayashi C, Mumby MC, Hannun YA. Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 1993; 268: 15523-15530.
173. Law B, Rossie S. The dimeric and catalytic supunit forms of protein phosphatase 2A from rat brain are stimulated by C2-ceramide. J Biol Chem 1995; 270: 12808-12813.
174. Galadari S, Kishikawa K, Kamibayashi C, Mumby MC, Hannun YA. Purification and characterization of ceramideactivated protein phosphatases. Biochemistry 1998; 37: 11232-11238.
175. Chalfant CE, Szulc Z, Roddy P, Bielawska A, Hannun YA. The structural requirements for ceramide activation of serinethreonine protein phosphatases. J Lipid Res 2004; 45: 496-506.
176. Kim SW, Kim HJ, Chun YJ, Kim MY. Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. J Toxicol Environ Health A 2010; 73: 1465-1476.
177. Singh AP, Bafna S, Chaudhary K, et al. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett 2008; 259: 28-38.
178. Bhardwaj A, Singh S, Srivastava SK, Honkanen RE, Reed E, Singh AP. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: Therapeutic implications. Mol Cancer Ther 2011; 10: 720-731.
179. Neuzil J, Weber T, Schröder A, et al. Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J 2001; 15: 403-415.
180. Park MA, Mitchell C, Zhang G, et al. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res 2010; 70: 6313-6324.
181. Mukhopadhyay A, Saddoughi SA, Song P, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 2009; 23: 751-763.
182. Christensen DJ, Ohkubo N, Oddo J, et al. Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 2011; 186: 2535-2542.
183. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011; 30: 2504-2513.
184. Ma L, Wen ZS, Liu Z, et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One 2011; 6: e20159.
185. Chen KF, Liu CY, Lin YC, et al. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010; 29: 6257-6266.
186. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 2010; 52: 88-95.
187. Chen KF, Yu HC, Liu CY, et al. Bortezomib Sensitizes HCC Cells to CS-1008, an Antihuman Death Receptor 5 Antibody, through the Inhibition of CIP2A. Mol Cancer Ther 2011; 10: 892-901.
188. Chen KF, Yeh PY, Hsu C, et al. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009; 284: 11121-11133.
189. Samanta AK, Chakraborty SN, Wang Y, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009; 28: 1669-1681.
190. Switzer CH, Ridnour LA, Cheng RY, et al. Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene 2009; 28: 3837-3846.
191. Guichard C, Pedruzzi E, Fay M, et al. Dihydroxyphenylethanol induces apoptosis by activating serine/threonine protein phosphatase PP2A and promotes the endoplasmic reticulum stress response in human colon carcinoma cells. Carcinogenesis 2006; 27: 1812-1827.
192. Chen L, Liu L, Yin J, Luo Y, Huang S. Hydrogen peroxideinduced neuronal apoptosis is associated with inhibition of protein phosphatase 2A and 5, leading to activation of MAPK pathway. Int J Biochem Cell Biol 2009; 41: 1284-1295.
193. Bianchini M, Martinelli G, Renzulli M, Gonzalez Cid M, Larripa I. CDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib. Cancer Chemother Pharmacol 2007; 59: 349-360.
194. Kalev P, Sablina AA. Protein phosphatase 2A as a potential target for anticancer therapy. Anticancer Agents Med Chem 2011; 11: 38-46.
195. McConnell JL, Wadzinski BE. Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol 2009; 75: 1249-1261.
196. De Wulf P, Montani F, Visintin R. Protein phosphatases take the mitotic stage. Curr Opin Cell Biol 2009; 21: 806-815.
197. Bollen M, Gerlich DW, Lesage B. Mitotic phosphatases: from entry guards to exit guides. Trends Cell Biol 2009; 19: 531-541.
198. Schmitz MH, Held M, Janssens V, et al. Live-cell imaging RNAi screen identifies PP2A-B55alpha and importin-beta1 as key mitotic exit regulators in human cells. Nat Cell Biol 2010; 12: 886-893.
199. Manchado E, Guillamot M, de Cárcer G, et al. Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl, and the PP2A/B55β phosphatase. Cancer Cell 2010; 18: 641-654.
200. Gharbi-Ayachi A, Labbé JC, Burgess A, et al. The supstrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A. Science 2010; 330: 1673-1677.
201. Mochida S, Maslen SL, Skehel M, Hunt T. Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis. Science 2010; 330: 1670-1673.
202. Lewy DS, Gauss CM, Soenen DR, Boger DL. Fostriecin: chemistry and biology. Curr Med Chem 2002; 9: 2005-2032.
203. Swingle MR, Amable L, Lawhorn BG, et al. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and(beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors. J Pharmacol Exp Ther 2009; 331: 45-53.
204. Roberge M, Tudan C, Hung SM, et al. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 1994; 54: 6115-6121.
205. Cheng A, Balczon R, Zuo Z, Koons JS, Walsh AH, Honkanen RE. Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity. Cancer Res 1998; 58: 3611-3619.
206. Liu D, Chen Z. The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem 2009; 9: 392-396.
207. Hill TA, Stewart SG, Sauer B, et al. Heterocyclic supstituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity. Bioorg Med Chem Lett 2007; 17: 3392-3397.
208. Hill TA, Stewart SG, Gordon CP, et al. Norcantharidin analogues: synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition. ChemMedChem 2008; 3: 1878-1892.
209. Kawada M, Amemiya M, Ishizuka M, Takeuchi T. Cytostatin, an inhibitor of cell adhesion to extracellular matrix, selectively inhibits protein phosphatase 2A. Biochim Biophys Acta 1999; 1452: 209-217.
210. Kawada M, Kawatsu M, Masuda T, et al. Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells. Int Immunopharmacol 2003; 3: 179-188.
211. Lawhorn BG, Boga SB, Wolkenberg SE, et al. Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition. J Am Chem Soc 2006; 128: 16720-16732.
212. Wada S, Usami I, Umezawa Y, et al. Rubratoxin A specifically and potently inhibits protein phosphatase 2A and suppresses cancer metastasis. Cancer Sci 2010; 101: 743-750.
213. Feng J, Wakeman T, Yong S, Wu X, Kornbluth S, Wang XF. Protein phosphatase 2A-dependent dephosphorylation of replication protein A is required for the repair of DNA breaks induced by replication stress. Mol Cell Biol 2009; 29: 5696-5709.
214. Wang Q, Gao F, Wang T, Flagg T, Deng X. A nonhomologous end-joining pathway is required for protein phosphatase 2A promotion of DNA double-strand break repair. Neoplasia 2009; 11: 1012-1021.
215. Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S, Lieberman J. Gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell 2005; 20: 801-8019.
216. Lu J, Kovach JS, Johnson F, et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci USA 2009; 106: 11697-116702.
217. Zhuang Z, Lu J, Lonser R, Kovach JS. Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome. Cell Cycle 2009; 8: 3303-3306.
218. Martiniova L, Lu J, Chiang J, et al. Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. PLoS One 2011; 6: e14678.
219. Chen LP, Lai YD, Li DC, et al. α4 is highly expressed in carcinogen-transformed human cells and primary human cancers. Oncogene 2011; 30: 2943-2953.
220. Sakashita S, Li D, Nashima N, et al. Overexpression of immunoglobulin (CD79a) binding protein1 (IGBP-1) in small lung adenocarcinomas and its clinicopathological significance. Pathol Int 2011; 61: 130-137.
221. Li D, Sakashita S, Morishita Y, et al. Binding of lactoferrin to IGBP1 triggers apoptosis in a lung adenocarcinoma cell line. Anticancer Res 2011; 31: 529-534.